VIDEO: Asciminib results could yield ‘significant change’ in CML treatment
Click Here to Manage Email Alerts
In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO Annual Meeting.
Winer, a medical oncologist at Dana-Farber Cancer Institute, highlighted a study that examined the use of the STAMP inhibitor asciminib (Scemblix, Novartis) in chronic myeloid leukemia rather than the more standard tyrosine kinase inhibitors or imatinib.
“If this bears out over time, then we may start to use asciminib more in the front-line setting, whereas right now it's really only approved in the third-line setting or in patients that have a T359 mutation. And so, this could be a significant change — an advance in the way we treat CML,” Winer said.
Collapse
Read more about
Click Here to Manage Email Alerts